Excellence in Pediatrics is a non-profit
global network dedicated to advancing
pediatric healthcare.
Rue des Vignerons 18, 1110 Morges 1 (VD), Switzerland
While RSV is well-known for overwhelming hospitals during peak seasons, its real and often underreported toll begins in pediatric clinics and private practices. The Excellence in Pediatrics Institute, with support from Sanofi, conducted an in-depth assessment to highlight the unseen burden, challenges, and opportunities to improve RSV diagnosis, treatment, and prevention where care starts—at the community level.
Primary care physicians and private pediatricians are often the first to encounter RSV cases. This survey uncovered a rising trend in both the volume and severity of RSV cases in infants—especially those aged 6–12 months. From prolonged symptoms and hospitalizations to disrupted daycare and family life, the impact extends beyond the clinic, putting pressure on already strained practices and communities.
The RSV Impact Assessment Survey reveals the scale and complexity of RSV’s burden across frontline care settings.
Children aged 6–12 months suffer disproportionately from RSV, with higher hospitalization rates and prolonged recovery.
Underuse of lab testing leaves many RSV cases unconfirmed, complicating both care and public health tracking.
While awareness of prevention is widespread among pediatricians, recommendations for vaccination remain inconsistent.
Most physicians expressed a strong need for updated clinical guidelines and hands-on training sessions.
The report identifies three critical areas that require immediate attention:
Explore findings from our multi-country survey of pediatric healthcare professionals and advocacy organisations.